Xibrom QD bromfenac: Phase III data

Data from a double-blind, placebo-controlled Phase III trial in 299 patients who underwent cataract surgery in one eye showed that once-daily Xibrom 0.09% met the primary endpoint of significantly increasing the absence of ocular inflammation 15 days following cataract surgery vs. placebo. Once-daily Xibrom also met the secondary endpoint of elimination of ocular pain at day 1 post-surgery. Xibrom was well tolerated with a safety profile consistent with the company's twice-daily Xibrom formulation, which is marketed in the U.S. to treat ocular inflammation and pain following cataract surgery. ...